Efficacy of xeligekimab in patients with active radiographic axial spondyloarthritis with and without elevated C-reactive protein or erythrocyte sedimentation rate: a post-hoc analysis of a phase III randomized clinical trial (EULAR 2026) - May 23, 2026 - Abstract #AB1027; B.1954; P3 | "Conclusions Xeligekimab demonstrated robust efficacy in r-axSpA patients regardless of baseline CRP or ESR. A higher proportion of patients returned to normal CRP or ESR levels at week 16 after receiving xeligekimab."
Clinical • P3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • CRP • IL17A
|
|
ZHEN TIAN1; Fang Kong1; Xia Li1; Qiuju Liao1; Li Su1; Xuemei Li1; Yi Zhao1
|